MAB_2355c Confers Macrolide Resistance in Mycobacterium abscessus by Ribosome Protection

Qi Guo,Yongjie Zhang,Junsheng Fan,Haonan Zhang,Zhemin Zhang,Bing Li,Haiqing Chu1Department of Respiratory Medicine,Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai 200433,China2Tongji University School of Medicine,Shanghai 200092,China3Shanghai Key Laboratory of Tuberculosis,Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai 200433,China
DOI: https://doi.org/10.1128/aac.00330-21
IF: 5.938
2021-06-08
Antimicrobial Agents and Chemotherapy
Abstract:Macrolide resistance is always a concern when treating Mycobacterium abscessus infections. MAB_2355c was identified previously as a possible new factor that confers the intrinsic resistance of 194 clinical M. abscessus isolates to clarithromycin. Herein, the potential mechanism by which MAB_2355c exerts macrolide resistance was explored by bioinformatics analysis, MAB_2355 cloning and protein purification, ATP hydrolysis assay, gene knockout and complementation, antibiotic sensitivity, and transcription-translation assays. MAB_2355c is a putative ATP-binding cassette F (ABC-F) family protein. Purified MAB_2355c protein exhibits ATP hydrolysis activity, which can be inhibited by ribosome-targeting antibiotics. MAB_2355c mRNA expression is upregulated more significantly after exposure to macrolides than exposure to other ribosome-targeting antibiotics. MAB_2355c deleted strains showed increased sensitivity to macrolides, which was reduced by MAB_2355c complementation. Finally, MAB_2355c rescued the transcription and translation activities affected by macrolides in vitro . These findings suggest that MAB_2355c confers the resistance of M. abscessus to macrolides by ribosome protection, thus complementing other known resistance mechanisms.
pharmacology & pharmacy,microbiology
What problem does this paper attempt to address?